Cancer Statistics, 2002

  title={Cancer Statistics, 2002},
  author={Ahmedin Jemal and Andrea Thomas and Taylor Murray and Michael J. Thun},
  journal={CA: A Cancer Journal for Clinicians},
Every year the American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival, using National Cancer Institute (NCI) incidence and National Center for Health Statistics (NCHS) mortality data. Incidence and death rates are age adjusted to the 1970 US standard population. It is estimated that 1,284,900 new cases of cancer will be diagnosed and 555,500… 

Prostate Cancer Incidence and Mortality Rates and Trends in the United States and Canada

Recent incidence patterns observed between the U.S. and Canada suggest a strong relationship to prostate-specific antigen (PSA) test use, and clinical trials are required to determine any effects of PSA test use on prostate cancer and overall mortality.

Evaluating quality of life in cancer survivors

Understanding how individuals who are cancer survivors manage the impact of cancer and experience the transformation of their lives is critical for health care professionals committed to assisting cancer patients and survivors in their recovery, for payers of health care, and for those engaged in policy regarding health insurance, employment, and disability-related rights of these many survivors.

Screening for Prostate Cancer: An Update of the Evidence

The burden of prostate cancer falls disproportionately on men who are older or black, and the incidence rate is approximately 60% higher and mortality rate is twofold higher in black men than in white men.

The Full Potential of Breast Cancer Screening Use to Reduce Mortality has not yet been Realized in the United States

Although there has been an increase in early-stage breast cancers (in situ and T1 tumors), the prerequisite decline in late-stage cancers has not yet occurred in the United States — a pattern that was observed in European studies.

Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force

A systematic review of the evidence on screening for prostate cancer found no direct evidence connecting screening and reduced mortality, and searched for indirect evidence on the yield of screening, the efficacy and harms of various forms of treatment for early prostate cancer, and the costs and cost-effectiveness.

A geographic analysis of prostate cancer mortality in the United States, 1970–89

The patterns observed could not be attributed to selected demographic or socioeconomic characteristics but should provide leads for further study into the risk factors and the medical or reporting practices that may contribute to geographic variation in mortality from prostate cancer.

The Epidemiology of Lung Cancer

This chapter will endeavor to highlight lung cancer incidence and mortality worldwide, identify changing trends in the lung cancer epidemic, and discuss the numerous etiologies of this deadly cancer.



Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends.

Overall cancer incidence and death rates continued to decline in the United States and future progress will require sustained improvements in cancer prevention, screening, and treatment.

Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

The decline in the incidence of distant stage disease holds the promise that testing for prostate-specific antigen may lead to a sustained decline in prostate cancer mortality, however, population data are complex, and it is difficult to confidently attribute relatively small changes in mortality to any one cause.

An adjustment to the 1997 estimate for new prostate cancer cases

It is now estimated that fewer than 210,000 new cases of prostate cancer may be diagnosed in 1997 than previously estimated.

Delineation of prognostic biomarkers in prostate cancer

Two genes—hepsin, a transmembrane serine protease, and pim-1, a serine/threonine kinase—are assessed at the protein level using tissue microarrays consisting of over 700 clinically stratified prostate-cancer specimens and linked clinical and pathology data are established.

Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification

The results suggest that two molecularly distinct forms of ccRCC exist and that the integration of expression profile data with clinical parameters could serve to enhance the diagnosis and prognosis ofccRCC.

Gene-expression profiles in hereditary breast cancer.

Significantly different groups of genes are expressed by breast cancers with BRCA1 mutations and breast cancersWith BRCa2 mutations, the results suggest that a heritable mutation influences the gene-expression profile of the cancer.

Predicting the clinical status of human breast cancer by using gene expression profiles

Bayesian regression models that provide predictive capability based on gene expression data derived from DNA microarray analysis of a series of primary breast cancer samples are developed and the utility and validity of such models in predicting the status of tumors in crossvalidation determinations are assessed.

Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling.

Gene expression analysis of prostate tissues should help to disclose the molecular mechanisms underlying prostate malignant growth and identify molecular markers for diagnostic, prognostic, and therapeutic use.

Molecular portraits of human breast tumours

Variation in gene expression patterns in a set of 65 surgical specimens of human breast tumours from 42 different individuals were characterized using complementary DNA microarrays representing 8,102 human genes, providing a distinctive molecular portrait of each tumour.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups.